. Author manuscript; available in PMC: 2013 Dec 20.

Published in final edited form as: Sci Transl Med. 2012 Feb 22;4(122):10.1126/scitranslmed.3003223. doi: 10.1126/scitranslmed.3003223

Table 2.

Presentation of breast cancer, other tumors, and cellular dysplasia in patients heterozygous for germline Abraxas c.1082G>A. TNM, tumor-node-metastasis; NA, data not available.

Patient	Breast cancer				Other cancer	Dysplasia
Patient	Morphology	Receptor status^*	TNM	Age at diagnosis/metastasis (years)	Other cancer	Dysplasia
BR-0194	Lobular	ER++, PR+++, HER2−	T2N1M0	53/bone, 62	—	Endometrial leiomyoma
B02	Lobular	ER+++, PR+++, HER2−	T3–4N1M0	45/bone, 48; brain, 51	—	—
BR-02101	Ductal	ER+++, PR+++, HER2−	T2N0M0	35/—	Endometrial, 48 years	—
98-063	Lobular/mucinous	ER+++, PR+++, HER2−	T1N0M0	49/—	—	Colon tubular adenoma (low-grade dysplasia)
96-653	Lobular	NA	T1N0M0	48/—	Skin, 71 years (lentigo maligna)	Colon tubular adenoma (low-grade dysplasia)

Positive staining for the ER and PR is defined as nuclear immunostaining in 1 to 10% (+), 10 to 50% (++), or >50% (+++) of the tumor cells, whereas a minus (−) indicates negative staining. Positive staining for HER2 is defined as membranous immunostaining of the tumor cells at levels + (faint positivity), ++ (moderate positivity), or +++ (strong, circumferential positivity), whereas HER2− indicates a completely negative staining.